Sugi Predict

Sugi Predict / Compounds / SCHEMBL6943174

SCHEMBL6943174

SCHEMBL6943174

Nc1ncnn2c1c(-c1ccc3cc[nH]c3c1)nc2[C@H]1CC[C@H](C(=O)O)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RIPK2 O43353 1/20 0.55
▸ RET P07949 1/20 0.55
▸ NQO2 P16083 1/20 0.55
▸ CSNK2A2 P19784 1/20 0.55
▸ FECH P22830 1/20 0.55
▸ ACVR1B P36896 1/20 0.55
▸ TGFBR1 P36897 1/20 0.55
▸ PIK3CA P42336 1/20 0.55
▸ MTOR P42345 1/20 0.55
▸ PIK3CG P48736 1/20 0.55
▸ MAPK10 P53779 1/20 0.55
▸ PRKDC P78527 1/20 0.55
▸ MAP2K5 Q13163 1/20 0.55
▸ BMPR2 Q13873 1/20 0.55
▸ RICTOR Q6R327 1/20 0.55
▸ RPTOR Q8N122 1/20 0.55
▸ PIP4K2C Q8TBX8 1/20 0.55
▸ MAPKAP1 Q9BPZ7 1/20 0.55
▸ MLST8 Q9BVC4 1/20 0.55
▸ NLK Q9UBE8 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6941293 0.89 TNK2 (0.68) RIPK2RETNQO2CSNK2A2FECH
SCHEMBL593697 0.87 IGF1R (0.63) PIK3CAMTORPIK3CGPRKDCTNK2
SCHEMBL12593625 0.84 TNK2 (0.65) PIK3CAMTORPIK3CGPRKDCRICTOR
SCHEMBL6939814 0.82 TNK2 (0.58) RIPK2RETNQO2CSNK2A2FECH
SCHEMBL595253 0.81 TNK2 (0.60) PIK3CAMTORPIK3CGPRKDCTNK2
SCHEMBL6942081 0.78 MTOR (0.72) RIPK2RETNQO2CSNK2A2FECH
SCHEMBL397534 0.75 IGF1R (0.79) RIPK2RETFECHMAP2K5PIP4K2C
SCHEMBL15291444 0.75 TNK2 (0.56) RIPK2RETNQO2CSNK2A2FECH
SCHEMBL7996206 0.75 MTOR (0.80) RIPK2RETNQO2CSNK2A2FECH
SCHEMBL2695691 0.74 MTOR (0.52) RIPK2RETNQO2CSNK2A2FECH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8796455-B2 Fused bicyclic mTOR inhibitors OSI Pharmaceuticals, LLC (US) 2014-08-05 — — US disclosed
US-8796455-B2 Fused bicyclic mTOR inhibitors OSI Pharmaceuticals, LLC (US) 2014-08-05 — — US disclosed
US-8586546-B2 Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors OSI Pharmaceuticals, LLC (US) 2013-11-19 — — US disclosed
US-8557814-B2 mTOR inhibitor salt forms OSI Pharmaceuticals, LLC (US) 2013-10-15 — — US disclosed
US-8557814-B2 mTOR inhibitor salt forms OSI Pharmaceuticals, LLC (US) 2013-10-15 — — US disclosed
EP-2385053-B1 Intermediates for the preparation of fused bicyclic mTOR inhibitors OSI PHARM INC (US) 2013-10-02 — — EP disclosed
US-20130165651-A1 FUSED BICYCLIC mTOR INHIBITORS OSI Pharmaceuticals, LLC 2013-06-27 — — US disclosed
US-20130165651-A1 FUSED BICYCLIC mTOR INHIBITORS OSI Pharmaceuticals, LLC 2013-06-27 — — US disclosed
US-8314111-B2 Fused bicyclic motor inhibitors OSI Pharmaceuticals, LLC (US) 2012-11-20 — — US disclosed
US-8314111-B2 Fused bicyclic motor inhibitors OSI Pharmaceuticals, LLC (US) 2012-11-20 — — US disclosed
US-20090274698-A1 Combination anti-cancer therapy OSI PHARMACEUTICALS, INC. 2009-11-05 — — US disclosed
US-20090274698-A1 Combination anti-cancer therapy OSI PHARMACEUTICALS, INC. 2009-11-05 — — US disclosed
WO-2009117482-A1 MTOR INHIBITOR SALT FORMS OSI PHARMACEUTICALS, INC (US) 2009-09-24 — — WO disclosed
US-20090163468-A1 Fused Bicyclic mTor Inhibitors OSI PHARMACEUTICALS, INC. 2009-06-25 — — US disclosed
US-20090163468-A1 Fused Bicyclic mTor Inhibitors OSI PHARMACEUTICALS, INC. 2009-06-25 — — US disclosed
WO-2009008992-A2 COMBINATION ANTI-CANCER THERAPY COMPRISING AN INHIBITOR OF BOTH MTORC1 AND MT0RC2 OSI PHARMACEUTICALS INC. (US) 2009-01-15 — — WO disclosed
US-20070280928-A1 Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors OSI PHARMACEUTICALS, INC. 2007-12-06 — — US disclosed
US-20070280928-A1 Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors OSI PHARMACEUTICALS, INC. 2007-12-06 — — US disclosed
US-20070112005-A1 mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer OSI PHARMACEUTICALS, INC. 2007-05-17 — — US disclosed
US-20070112005-A1 mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer OSI PHARMACEUTICALS, INC. 2007-05-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163468-A1 Fused Bicyclic mTor Inhibitors MTOR, RICTOR, MAPKAP1 RIPK2 1316/4885RET 744/4885NQO2 2722/4885
US-20130165651-A1 FUSED BICYCLIC mTOR INHIBITORS MTOR, RICTOR, MAPKAP1 RIPK2 1316/4885RET 744/4885NQO2 2722/4885
US-20090274698-A1 Combination anti-cancer therapy MTOR, RICTOR, AKT1 RIPK2 695/4885RET 1023/4885NQO2 3455/4885
US-20070280928-A1 Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors EGFR, ERBB2, RICTOR RIPK2 288/4885RET 60/4885NQO2 3037/4885
US-20070112005-A1 mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer MTOR, MAPKAP1, RPS6KA1 RIPK2 433/4885RET 1262/4885NQO2 4011/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.